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It is widely acknowledged that single-use bioreactors can increase flexibility, reduce production costs, and 
improve productivity. Consequently, a multitude of single-use bioreactors, which greatly differ in geometry, size, 
agitation principle, sensors, and cultivation performance, have been developed over the last decade. In modern 
biomanufacturing processes, mechanically driven bioreactors, including stirred, wave-mixed and orbitally 
shaken systems, dominate due the extensive anecdotal and published information as well as readily available 
engineering data, and scale-up capabilities. These single-use bioreactors are primarily used for seed train and 
inoculum production but are also employed for vaccine and monoclonal antibody manufacturing.  
Driven by market adoption and evolution, Finesse Solutions has recently focused on expanding its 
SmartVessel™ bioreactor family. Based on fluid dynamic investigations that were conducted during early design 
studies, prototypes of a new single-use bioreactor were built by using rapid prototyping techniques. A variety of 
rapid prototyping techniques, such as stereolithography (SLA), laser sintering and 3D printing are now viable for 
this application and currently available for commercial use. Additionally, a large variety of different plastic 
materials are also available. Finding materials suitable for use in a cGMP environment is however still 
challenging; the polymers have to meet special requirements, including the absence of animal-component 
derived material, Bisphenol A (BPA), latex free, phthalate free – and must also be free of cytotoxic and 
carcinogenic components. Ideally the materials that meet the aforementioned criteria are also gamma irradiation 
compatible to levels in excess of 40 kGy.  
 
Based on a case study, this presentation provides some insights into the developmental process from 
conceptional bioreactor designs to a final product. Special focus is on the rapid prototyping that can enable 
faster time to market and reduced costs and the dichotomy between a rapid prototyped part and a molded part. 
Furthermore, aspects of the material selection with regards to cGMP compliance and stability for gamma 
irradiation are discussed. 
 
